Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corp executive Nathaniel Sisitsky, the Chief Legal Officer, has filed an initial ownership report indicating that he currently holds no securities beneficially owned in the company. The filing shows total direct holdings of 0 shares following the reported position.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported routine equity compensation activity involving restricted stock units and related tax withholding. On the transaction date, 4,925 restricted stock units were released, converting into 4,925 shares of common stock as part of previously reported awards.
Of these shares, 1,519 were withheld by the company at $14.78 per share to satisfy tax withholding obligations tied to the RSU release, which is not an open-market sale. Following these transactions, Busky held 44,818 shares of common stock directly and 10,290 shares indirectly through a trust.
QuidelOrtho Corp received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard reports 0 shares beneficially owned of QuidelOrtho common stock.
The filing explains certain subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.
QuidelOrtho Corp executive vice president Bryan Michael Hanson filed an initial ownership report showing existing equity awards rather than new trades. He directly holds multiple incentive and non-qualified stock options on common stock with exercise prices ranging from $27.17 to $179.06, plus several restricted stock unit grants, including one for 36,152 underlying shares, and 900 common shares. Footnotes detail vesting schedules through dates such as July 1, 2028 and January 30, 2029, with each restricted stock unit convertible into one common share.
QuidelOrtho Corporation announced a planned leadership transition in its top legal role. Chief Legal Officer and Corporate Secretary Michelle A. Hodges will retire from these positions effective March 23, 2026, with a transition and retirement agreement supporting an orderly handover of her duties.
For up to six months, Ms. Hodges will continue receiving her current base salary and benefits while transitioning responsibilities. She will then serve as special advisor to the Chief Executive Officer for up to twenty-four months, initially at her current base salary rate, which will be reduced by 50% for the remainder of the advisory term, while remaining eligible for employee benefits, annual bonus and equity grant opportunities, and continued vesting of existing equity awards.
The Board of Directors appointed Nathaniel “Nate” Sisitsky as the new Chief Legal Officer and Corporate Secretary, effective as of the same date. With more than 25 years of legal and governance experience at public life sciences and technology companies, including prior Chief Legal Officer and Corporate Secretary roles, he will lead QuidelOrtho’s global legal, compliance and corporate governance functions.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an amended insider transaction reflecting an open-market purchase of 3,370 shares of common stock on February 13, 2026, acquired indirectly through a trust at a weighted average price of $23.6623 per share.
The amendment corrects the pricing details, noting a purchase price range from $23.0150 to $23.6750 per share. Following these transactions, Busky’s indirect holdings held by a trust total 10,290 shares, and his direct ownership stands at 41,412 shares of QuidelOrtho common stock.
QuidelOrtho Corporation provides a detailed annual overview of its global diagnostics business, spanning Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine across more than 140 countries. The company highlights U.S. manufacturing and service scale, including about 6,500 employees and roughly 1,200 service staff.
QuidelOrtho is winding down its U.S. donor screening portfolio, including the VIP platform and microplate assays, with completion expected by the first half of 2026, and has decided to discontinue development of the SAVANNA molecular platform. Respiratory products represented about 15% of total 2025 revenues, reflecting strong seasonality.
The company continues to invest in R&D, with expenses of $186.2 million, $218.7 million and $245.0 million for fiscal years 2025, 2024 and 2023, respectively. It recorded a $65 million charge payable to Grifols over three years tied to mutually agreed terms in principle for an early termination of their long‑running Joint Business arrangement. As of February 11, 2026, 68,081,767 common shares were outstanding, and the aggregate market value of common stock held by non‑affiliates was $1,940,523,408 as of the last business day of the most recent second fiscal quarter.
QuidelOrtho Corporation reported that its Chief Financial Officer and principal financial officer, Joseph M. Busky, has informed the company of his plans to retire, effective June 30, 2026. The company states that his decision is for personal reasons and not due to any disagreement regarding financial statements, operations, policies, or practices. This advance notice gives QuidelOrtho time to manage the transition in its senior financial leadership.
Strobeck Matthew reported open-market purchase transactions in a Form 4 filing for QDEL. The filing lists transactions totaling 10,000 shares at a weighted average price of $23.96 per share. Following the reported transactions, holdings were 27,775 shares.
QuidelOrtho Corporation received an amended ownership report showing that investment adviser Rubric Capital Management LP and David Rosen together beneficially own 3,777,157 shares of QuidelOrtho common stock, representing 5.56% of the outstanding shares.
The filing states Rubric Capital advises funds that hold these shares, including Rubric Capital Master Fund LP, which has the right to receive dividends or sale proceeds on more than 5% of the stock. The securities are reported as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.